2025, Session Coverage
  • Dr. Felicia Hill-Briggs Health Equity Trailblazers in Diabetes Award debuts

    Dr. Felicia Hill-Briggs Health Equity Trailblazers in Diabetes Award debuts

    A leading scholar in epidemiology and health equity, Tiffany L. Gary-Webb, PhD, MHS, will receive the inaugural Dr. Felicia Hill-Briggs Health Equity Trailblazers in Diabetes Award.


  • Panel will discuss impact of SGLT2 inhibitors and GLP-1 drugs on diabetes complications and health care costs

    Panel will discuss impact of SGLT2 inhibitors and GLP-1 drugs on diabetes complications and health care costs

    Celeste Thomas, MD, will present the adult care perspective. Other panelists will examine the impact of these medications from the pediatric care, health system, and patient viewpoints.


  • Symposium will detail nuances of treating type 2 diabetes

    Symposium will detail nuances of treating type 2 diabetes

    Kristina Utzschneider, MD, and other experts will discuss the individual dynamics of managing patients with type 2 diabetes who are lean, are prone to ketosis, or have end-stage liver or renal disease.


  • Scientific Sessions open with updates on translating clinical advances into routine care

    Scientific Sessions open with updates on translating clinical advances into routine care

    Osagie Ebekozien, MD, MPH, the first-ever Chief Quality Officer of the American Diabetes Association® (ADA), underscored the philosophy driving initiatives moving the Standards of Care in Diabetes into routine practice. Among them, an effort to destigmatize obesity and promote its treatment as a chronic disease.


  • Pathway to Stop Diabetes® grants help advance diabetes understanding and care

    Pathway to Stop Diabetes® grants help advance diabetes understanding and care

    Sarah Stanley, MB, BCh, PhD, and other grant recipients shared new understanding around diabetes made possible through early-career awards from the ADA.


  • Experts to explore future of emerging non-peptide, small molecule GLP-1 receptor agonists

    Experts to explore future of emerging non-peptide, small molecule GLP-1 receptor agonists

    An international panel will discuss small nonpeptide GLP-1 receptor agonists and what this research means for the outlook of diabetes treatment. Julio Rosenstock, MD, will present data from ACHIEVE-1, a trial for the oral GLP-1 receptor agonist orforglipron.


  • Session to explain ADA guidelines on liver disease in diabetes

    Session to explain ADA guidelines on liver disease in diabetes

    Experts, including Mandeep Bajaj, MBBS, will discuss what is considered the most underdiagnosed complication of diabetes—metabolic dysfunction-associated steatotic liver disease.


  • Pilot project delivers training on obesity bias and weight care in primary care practice

    Pilot project delivers training on obesity bias and weight care in primary care practice

    Jack Westfall, MD, MPH, and others will explain ways the ADA is supporting efforts to overcome weight bias, improve pharmacy connections, and optimize access to technology in the primary care setting.


  • Session will explore antigen targets underpinning autoimmunity in type 1 diabetes

    Session will explore antigen targets underpinning autoimmunity in type 1 diabetes

    Emrah Altindis, PhD, and other panelists will describe the intricacies of targets such as B cells, autoantibody sources that also serve as antigen-presenting cells, and CD4-positive T cells.


  • Experts will discuss the importance of considering identity to enhance diabetes care

    Experts will discuss the importance of considering identity to enhance diabetes care

    Among the speakers, Elise Van Laere will give an overview of responses to an illness identity questionnaire that explores multiple ways individuals relate to their diabetes, and the impact those have on diabetes-specific and psychosocial outcomes.